Zhong Zhen Guan

Summary

Affiliation: Sun Yat-sen University
Country: China

Publications

  1. doi request reprint Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
    Zhongzhen Guan
    Sun Yat sen University Cancer Center, Guangzhou, China
    J Clin Oncol 31:1947-53. 2013
  2. pmc Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
    Zhong Zhen Guan
    Department of Medical Oncology, Sun Yat sen University Cancer Center, Guangzhou, People s Republic of China
    Chin J Cancer 30:682-9. 2011
  3. ncbi request reprint [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1687-91. 2004
  4. ncbi request reprint [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]
    Hong Yu Zhang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1681-6. 2004
  5. ncbi request reprint [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]
    Yu Long Peng
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:943-6. 2004
  6. ncbi request reprint Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma
    Yu Hong Li
    Department of Medical Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in Southern China, 651 Dong Feng Road East, Guangzhou 510060, People s Republic of China
    Cancer 106:1320-5. 2006
  7. ncbi request reprint [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]
    Rui Hua Xu
    Sun Yat sen University Cancer Center, Guangzhou 510060, China
    Zhonghua Yi Xue Za Zhi 83:191-4. 2003
  8. ncbi request reprint [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:389-92. 2003
  9. ncbi request reprint [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma]
    Hong Yu Zhang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 30:381-4. 2008
  10. ncbi request reprint [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts]
    Shu Sen Wang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PRChina
    Ai Zheng 23:1365-9. 2004

Collaborators

Detail Information

Publications48

  1. doi request reprint Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
    Zhongzhen Guan
    Sun Yat sen University Cancer Center, Guangzhou, China
    J Clin Oncol 31:1947-53. 2013
    ..This study is designed to test whether the addition of lapatinib to paclitaxel improves overall survival (OS) compared with placebo plus paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)...
  2. pmc Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
    Zhong Zhen Guan
    Department of Medical Oncology, Sun Yat sen University Cancer Center, Guangzhou, People s Republic of China
    Chin J Cancer 30:682-9. 2011
    ..Clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients...
  3. ncbi request reprint [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1687-91. 2004
    ..BFM-90 regimen for lymphoblastic lymphoma is one of the most effective regimens. This study was designed to evaluate efficacy and toxicities of modified BFM-90 regimen on Chinese children and adolescents with lymphoblastic lymphoma...
  4. ncbi request reprint [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]
    Hong Yu Zhang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1681-6. 2004
    ..This study was to determine efficacy and safety of the combination of rituximab and chemotherapy in treating Chinese patients with aggressive B-NHL, and to analyze influence factors on the response...
  5. ncbi request reprint [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]
    Yu Long Peng
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:943-6. 2004
    ..It shows low chemosensitivity, high incidence of relapse, poor prognosis, and has no standard chemotherapy regimen. The efficacy of CHOP is poor for PTCL. This study was to evaluate the efficacy and toxicity of EPOCH regimen for PTCL...
  6. ncbi request reprint Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma
    Yu Hong Li
    Department of Medical Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in Southern China, 651 Dong Feng Road East, Guangzhou 510060, People s Republic of China
    Cancer 106:1320-5. 2006
    ..The objective of the current study was to assess the value of antiviral lamivudine for reducing the incidence and severity of hepatitis in HBV carriers with lymphoma who receive chemotherapy...
  7. ncbi request reprint [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]
    Rui Hua Xu
    Sun Yat sen University Cancer Center, Guangzhou 510060, China
    Zhonghua Yi Xue Za Zhi 83:191-4. 2003
    ..To analyze the curative effect of aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis...
  8. ncbi request reprint [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:389-92. 2003
    ..The purpose of this study was to evaluate the efficacy and toxicity of EPOCH regimen...
  9. ncbi request reprint [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma]
    Hong Yu Zhang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 30:381-4. 2008
    ..To investigate the relationship of clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma (DLBCL)...
  10. ncbi request reprint [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts]
    Shu Sen Wang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PRChina
    Ai Zheng 23:1365-9. 2004
    ..The present study was designed to evaluate the effect of Gefitinib alone or in combination with cisplatin (DDP) on NPC CNE2 xenografts...
  11. ncbi request reprint [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]
    Yu Hong Li
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:401-3. 2003
    ..However,no standard treatment regimen ever established for nasopharyngeal lymphoma(NPL). The purpose of this paper is to investigate the clinical characteristics and treatment results of NPL...
  12. ncbi request reprint [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 23:1443-7. 2004
    ....
  13. ncbi request reprint High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers
    Feng Wang
    Department of Medical Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou, People s Republic of China
    Cancer 109:1360-4. 2007
    ..The authors investigated the prevalence of hepatitis B virus (HBV) infection by using serologic markers in non-Hodgkin lymphoma (NHL) compared with other types of cancers in Chinese patients...
  14. ncbi request reprint [Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma]
    Hui Qiang Huang
    State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat Sen University, Cancer Center, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 30:314-6. 2008
    ..This clinical study was designed to evaluate the efficacy and toxicity of the combined regimen of docetaxel, 5-Fu and DDP (TPF) in the treatment of advanced or relapsed nasopharyngeal carcinoma (NPC)...
  15. ncbi request reprint [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma]
    Xiao Fei Sun
    Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Cancer Center of Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 29:58-61. 2007
    ..This study was designed to evaluate the efficacy and toxicity of modified BFM-90 regimen originated from Germany authors in the treatment of Chinese childhood and adolescent lymphoblastic lymphoma...
  16. doi request reprint High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy
    Zhi Ming Li
    State Key Laboratory of Oncology in Southern China, Sun Yat Sen University, Guangzhou, Guangdong, China
    Eur J Haematol 88:510-7. 2012
    ..This study aimed to investigate whether Ki-67 expression is an indicator of outcome in DLBCL patients (especially non-GCB DLBCL patients) treated with standard chemotherapy combined with rituximab...
  17. ncbi request reprint [Survival outcomes of T-cell non-Hodgkin's lymphoma: a report of 111 cases]
    Yan Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 24:470-4. 2005
    ..T-cell non-Hodgkin's lymphoma (NHL) is a group of heterogeneous malignancies with poor prognosis, and without ideal therapeutic regimen. This study was to summarize clinical and pathologic features of T-cell NHL...
  18. doi request reprint The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma
    Yi Fu He
    Department of Medical Oncology, Sun Yat sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, 510060, People s Republic of China
    Ann Hematol 87:481-5. 2008
    ..Consequently, our study confirmed previous reports that prophylactic lamivudine therapy can prevent HBV reactivation in HBV carriers who were receiving rituximab-containing regimen for lymphoma...
  19. ncbi request reprint Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center of Sun Yat Sen University, Guangzhou, People s Republic of China
    Eur J Haematol 77:365-71. 2006
    ....
  20. ncbi request reprint [Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study]
    Li Kun Chen
    Department of Internal Medicine, Cancer Center, Sun Yat Sen University, Guangzhou, 510060, China
    Zhonghua Zhong Liu Za Zhi 29:437-40. 2007
    ..To investigate the therapeutic effect, long term survival and side effect on NSCLC patients treated with nadaplatin combined with paclitaxol and cisplatin combined with paclitaxol...
  21. ncbi request reprint [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor]
    Xiao yu Teng
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 23:1431-6. 2004
    ....
  22. ncbi request reprint [Clinical characteristics and prognosis of different subtypes of breast cancer]
    Zhong Yu Yuan
    State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Cancer Center, Sun Yat sen Unversity, Guangzhou
    Zhonghua Zhong Liu Za Zhi 30:456-61. 2008
    ..To investigate the clinical characteristics and prognosis of patients with different subtypes of breast cancer: basaloid, HER-2 and luminal types, and try to find the evidence of individualized treatment for the patients...
  23. ncbi request reprint [Distribution of CD8+CD28- T cells and CD3+CD56+ NKT cells in peripheral blood of patients with B-cell non-Hodgkin's lymphoma]
    Yan Xia Shi
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 23:1437-42. 2004
    ....
  24. ncbi request reprint [Significance of EGFR and p-ERK expression in nasopharyngeal carcinoma]
    Shu Sen Wang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 28:28-31. 2006
    ..To detect the expression of EGFR and p-ERK in nasopharyngeal carcinoma (NPC) and investigate their clinical significance...
  25. ncbi request reprint [CD4+CD25+T regulatory cells in peripheral blood of B-NHL patients with or without chemotherapy]
    Yan Xia Shi
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:597-601. 2004
    ....
  26. ncbi request reprint [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer]
    Bo Wang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1710-3. 2004
    ..This study was designed to investigate discordance of ER, PR,and HER-2 statuses between primary and metastatic focuses of breast cancer...
  27. pmc Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
    Feng Wang
    State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat sen University Cancer Center, Guangzhou, PROC
    BMC Cancer 8:115. 2008
    ..The main objective of the current study was to analyze the clinical features and to evaluate the prognostic factors of HBV infection in DLBCL patients...
  28. ncbi request reprint [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:448-51. 2004
    ..Significantly higher response rate can be yielded by combined regimen such as FN, FMD, and FC, etc. The purpose of this study was to investigate the efficacy and toxicity of fludarabine-based regimen for patients with lymphoma in China...
  29. ncbi request reprint [Multivariate survival analysis for 423 patients with non-small cell lung cancer]
    Wei Wang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:624-8. 2003
    ..New prognostic factors are needed to guide the treatment of patients with NSCLC. This study was designed to evaluate the characteristics and outcome in NSCLC patients who underwent completely surgical resection...
  30. doi request reprint Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma
    Ying Jie Zhu
    State Key Laboratory of Oncology in Southern China, Sun Yat Sen University, Guangzhou, Guangdong, People s Republic of China
    Med Oncol 29:1127-33. 2012
    ..Our findings demonstrated that some clinical characteristics of Hodgkin's lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage...
  31. ncbi request reprint [Clinical significance of quantitative analysis of serum VEGF, CD44s, and MMP-3 protein in nasopharyngeal carcinoma]
    Yu Hong Li
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:1060-4. 2004
    ..This study was to investigate the correlation of serum vascular endothelial growth factor (sVEGF), CD44 standard (CD44s), and matrix metalloproteinase-3 (MMP-3) level to the clinical outcomes in nasopharyngeal carcinoma (NPC)patients...
  32. ncbi request reprint Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
    Li Zhang
    Department of Medical Oncology, Cancer Center of Sun Yat Sen University, 651 Dongfeng Road East, Guangzhou, 510060, People s Republic of China
    Cancer Chemother Pharmacol 61:33-8. 2008
    ..This study was designed to evaluate the anti-tumor activity and toxicity profile of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma (NPC) who had been pretreated with platinum-based chemotherapy...
  33. pmc The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials
    Li Zhang
    Department of Medical Oncology, Sun Yat sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China
    BMC Cancer 10:558. 2010
    ....
  34. ncbi request reprint [A survival of 103 cases of T-cell non-Hodgkin lymphoma]
    Yan Xia Shi
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, China
    Zhonghua Nei Ke Za Zhi 46:1000-2. 2007
    ..T-cell non-Hodgkin lymphoma was heterogeneous and relatively high incident in our country. It's response and prognosis were poor. This study was to analyze clinical feature and survival of T-NHL...
  35. ncbi request reprint [Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:1334-8. 2003
    ..The purpose of this study was to investigate the efficacy, toxicity, and proper dosage of TUOXI as single agent in treatment of advanced and recurrent solid tumors...
  36. ncbi request reprint [Effect of expression of coxsackie and adenovirus receptor on antitumor activity of genetically modified adenovirus]
    Zhong Yu Yuan
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 24:502-5. 2005
    ..This study was to evaluate relationship of CAR expression to infectivity and efficacy of adenovirus...
  37. doi request reprint A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer
    Hui Yan Luo
    Department of Medical Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou, People s Republic of China
    Chemotherapy 54:228-35. 2008
    ..To evaluate the efficacy and toxicity of an oxaliplatin, fluorouracil (5-FU), and folinic acid (FOLFOX-6) combination therapy in patients with advanced or recurrent gastric cancer...
  38. ncbi request reprint [Primary breast lymphoma--a report of 27 cases with literature review]
    Ya Bing Cao
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:84-9. 2007
    ..Primary breast lymphoma (PBL) is an uncommon disease with poor clinical outcome. This study was to investigate clinicopathologic features and optimal treatment of PBL...
  39. ncbi request reprint [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial]
    Zhong Zhen Guan
    Skate Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, P R China
    Ai Zheng 24:980-4. 2005
    ..This study, a multicenter clinical trial, was designed to evaluate the efficacy of gefitinib on Chinese patients with locally advanced or metastatic NSCLC after failure of previous chemotherapy, and explore its safety...
  40. ncbi request reprint [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes]
    Pin Zhang
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, China
    Zhonghua Yi Xue Za Zhi 92:3345-9. 2012
    ..To evaluate the efficacy and safety of 1-year adjuvant trastuzumab (herceptin) versus 1-year non-trastuzumab observation in Chinese patients with HER2-positive early breast cancer during a median follow-up of 1 year...
  41. ncbi request reprint [Antitumor immune responses induced by idiotype-pulsed dendritic cells with cell-penetrating peptide vaccination in vivo]
    Jian hua Chang
    Department of Medical Oncology, Fudan University Tumor Hospital, Shanghai 200032, China
    Zhonghua Zhong Liu Za Zhi 29:804-7. 2007
    ..To confirm the therapeutic effect of dendritic cell (DC) vaccine on treatment for mice with lymphoma and the protective effect of DC vaccine loaded with different antigens on the tumor-bearing BAL B/c mice...
  42. pmc Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning
    Xing Zhang
    Department of Medical Oncology, Sun Yat sen University Cancer Center, Guangzhou, 510060, China
    BMC Cancer 7:235. 2007
    ..In this study, we used serum proteomic mass spectra to identify potential serum biomarkers and biomarker patterns for detecting DLBCL and patient responses to therapy...
  43. doi request reprint Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center of Sun Yat Sen University, 651 Dongfeng Road, East Guangzhou 510060, People s Republic of China
    Int J Clin Oncol 13:436-41. 2008
    ..This study was designed to evaluate the efficacy and toxicity of a modified acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with LBL...
  44. ncbi request reprint [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)]
    He Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 31:148-51. 2009
    ..The aim of this study is to evaluate the efficacy and safety of Gefitinib in the treatment of Chinese patients with recurrent advanced non-small-cell lung cancer (NSCLC)...
  45. ncbi request reprint [Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin]
    Rui Hua Xu
    Skate Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, P R China
    Ai Zheng 24:975-9. 2005
    ..To date, no appropriate reversal agent is used clinically. This study was to evaluate reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin (DDP), and to explore its mechanisms...
  46. ncbi request reprint [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]
    Hui Qiang Huang
    State Key Laboratory of Oncology in South China, Guangzhou, Gongdong 510060, P R China
    Ai Zheng 25:486-9. 2006
    ..This study was to evaluate the efficacy of rituximab-containing salvage regimens on relapsed or refractory NHL, and observe the toxicities...
  47. ncbi request reprint [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases]
    Zhong Jun Xia
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 25:490-4. 2006
    ..This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China...
  48. ncbi request reprint [Extrapulmonary small cell carcinoma in 52 patients]
    Zhong Yu Yuan
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 25:1131-3. 2006
    ..Extrapulmonary small cell carcinoma (ESCC) has been recognized as a clinicopathologic entity distinct from small cell carcinoma of the lung. The study was to investigate the clinical characteristics, therapy, and prognosis of ESCC...